HTS and Bulk FAQs

Question 1:  What kind of references do you have for Cytoskeleton's products used in drug screening?

Question 2:   What kind of discounts can I expect for bulk purchases? 

Question 3:  Will Cytoskeleton help me develop my drug screen?


Question 1: What kind of references do you have for Cytoskeleton's products used in drug screening? 

Answer 1:Cytoskeleton, Inc. has been a reliable source of protein reagents for drug screening for nearly two decades. Past clients include:

Merck         Eli Lilly         Amgen         Abbott Labs        GlaxoSmithKline

Genentech       Johnson & Johnson       Bristol -Myers Squibb        Pfizer        Wyeth

We support all of our products with a dedicated technical services department and years of experience in the fields of cell biology, cancer biology and neuroscience.

Some of the bulk purchases intended for screening projects are related to proprietary research, potentially limiting the number of citations available.  Here are a select few recent publications that used our motor protein and/or tubulin products.


Mi et al., 2008.  Covalent Binding to Tubulin by Isothiocyanates: A mechanism of cell growth arrest and apoptosis.  J. Biol. Chem. 283, 22136–22146.


Gorenstein et al., 2010. Reducing the multidimensionality of high-content screening into versatile powerful descriptors. BioTechniques. 49, 663-665.


Meng et al., 2008.  A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Cancer Chemother. Pharmacol. 61, 953-963.


Motor protein antibody)  Endo et al., 2009. Truncated form of tenascin-X, XB-S, interacts with mitotic motor kinesin Eg5. Mol. Cell. Biochem. 320, 53-66.


Xing et al., 2011.  A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. Asian J. Androl. 13, 236-241.


Rodriguez et al., 2011.  Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity. Bioorg. Med Chem. 19, 5446-5453.


Grigoryan  et al., 2009.  Covalent binding of the organophosphorus agent FP-biotin to tyrosine in eight proteins that have no active site serine. Chem. Biol. Interact. 180, 492–498.


Dinu et al. 2009.  Tubulin Encapsulation of Carbon Nanotubes into Functional Hybrid Assemblies. Small. 5, 310–315.


Wasylycia et al., 2008.  Nano-biopower supplies for biomolecular motors: the use of metabolic pathway-based fuel generating systems in microfluidic devices.  Lab Chip. 8, 979-982.



Question 2: What kind of discounts can I expect for bulk purchases?  

Answer 2: Cytoskeleton, Inc. wants to help your project be successful in any way that we can.  We are aware of budget constraints on projects and will do our best to work with you to reach a pricing structure amenable to everyone.  The actual discount will depend on the particular product, but 20-50% discounts are not uncommon for quantities of 50 or more.



Question 3: Will Cytoskeleton help me develop my drug screen?

Answer 3: Cytoskeleton, Inc. will help with optimizing conditions prior to initiating the experimental assays.  We can offer suggestions and guidance for (i) choosing optimal experimental conditions, (ii) designating optimal equipment settings and (iii) performing equipment trouble-shooting.